Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T9TE
|
|||
| Drug Name |
Ombitasvir + paritaprevir + ritonavir
|
|||
| Synonyms |
ABT-267/ABT-450/ritonavir; ABT-267/ritonavir/ABT-450; ABT-450/ABT-267/ritonavir; ABT-450/r + NS5A; ABT-450/r/ABT-267; ABT-450/ritonavir/ABT-267; HOLKIRA PAK; OBV/PTV/r; Ombitasvir/ABT 450/ritonavir; Ombitasvir/ritonavir/ABT-450; Ombitasvir/ritonavir/veruprevir; Paritaprevir/ombitasvir/ritonavir; Ritonavir/ABT 450/ombitasvir; Ritonavir/ABT-267/ABT-450; Ritonavir/ABT-450/ABT-267; Ritonavir/ombitasvir/ABT-450; Ritonavir/ombitasvir/paritaprevir; Ritonavir/veruprevir/ombitasvir; TECHNIVIE; Veruprevir/ombitasvir/ritonavir; Viekira Pak (ombitasvir/paritaprevir/ritonavir combination therapy); Viekirax
Click to Show/Hide
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Approved | [1] | |
| Therapeutic Class |
Antiinfective Agents
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Hepatitis C virus NS3 helicase (HCV NS3) | Target Info | Modulator | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2015. Application Number: (ANDA) 207931. | |||
| REF 2 | HCV Drug Resistance Challenges in Japan: The Role of Pre-Existing Variants and Emerging Resistant Strains in Direct Acting Antiviral Therapy | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.